论文部分内容阅读
目的:探讨抗血管生成药物Bevacizumab联合吉西他滨对人肝癌裸鼠皮下移植瘤生长的抑制作用。方法:构建人肝癌细胞HepG2裸鼠皮下移植瘤模型,随机分为空白对照组、Bevacizumab组、吉西他滨组和联合用药组。观察用药前后肿瘤体积,绘制肿瘤生长曲线;应用免疫组化检测肿瘤微血管密度(MVD);Western Blot检测Bcl-2蛋白的表达。结果:Bevacizumab和吉西他滨单药均能抑制肿瘤生长,两药联合疗效明显增强(P=0.000)。与对照组和吉西他滨组相比,Bevacizumab组和联合用药组能明显抑制肿瘤血管生成,MVD值均明显降低,以联合用药组最为明显(P均0.000)。Bevacizumab和吉西他滨单药均能下调Bcl-2的表达,两药联合下调作用明显增强。结论:Bevacizumab联合吉西他滨能增强对人肝癌裸鼠移植瘤的生长及微血管生成的抑制作用,其机制可能与调控Bcl-2的表达有关。
Objective: To investigate the inhibitory effect of Bevacizumab combined with gemcitabine on the growth of human hepatocellular carcinoma xenografts in nude mice. Methods: Human hepatocellular carcinoma HepG2 cells were transplanted subcutaneously in nude mice and were randomly divided into blank control group, Bevacizumab group, gemcitabine group and combination group. The tumor volume was observed before and after treatment, and the tumor growth curve was drawn. The tumor microvessel density (MVD) was detected by immunohistochemistry. The expression of Bcl-2 protein was detected by Western Blot. Results: Both Bevacizumab and gemcitabine could inhibit the growth of the tumor, and the combined effect of the two drugs was significantly enhanced (P = 0.000). Compared with control group and gemcitabine group, Bevacizumab group and combination group could significantly inhibit tumor angiogenesis, MVD values were significantly reduced, the combination group was the most obvious (P 0.000). Both Bevacizumab and gemcitabine could down-regulate the expression of Bcl-2, and the combined effect of the two drugs was significantly enhanced. Conclusion: Bevacizumab combined with gemcitabine can enhance the inhibition of the growth and angiogenesis of human hepatocellular carcinoma xenografts in nude mice. The mechanism may be related to the regulation of Bcl-2 expression.